TAXOTERE

国家: 以色列

语言: 英文

来源: Ministry of Health

有效成分:

DOCETAXEL AS TRIHYDRATE 20 MG / 1 ML

可用日期:

SANOFI - AVENTIS ISRAEL LTD

ATC代码:

L01CD02

药物剂型:

CONCENTRATE FOR SOLUTION FOR INFUSION

给药途径:

I.V

厂商:

SANOFI - AVENTIS DEUTSCHLAND GMBH, GERMANY

治疗组:

DOCETAXEL

疗效迹象:

Breast cancer: Taxotere (docetaxel) in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node- positive breast cancer. Taxotere (docetaxel) in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition. Taxotere(docetaxel) monotherapy is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent. Taxotere (docetaxel) in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumors overexpress HER2 and who previously have not received chemotherapy for metastatic disease. Taxotere (docetaxel) in combination with capecitabine is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic chemotherapy.

授权日期:

2012-11-01